title: Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.
abstract: The syndecans are a family of heparan sulfate-decorated cell-surface proteoglycans: matrix receptors with roles in cell adhesion and growth factor signaling. Their heparan sulfate chains recognize 'heparin-binding' motifs that are ubiquitously present in the extracellular matrix, providing the means for syndecans to constitutively bind and cluster to sites of cell-matrix adhesion. Emerging evidence suggests that specialized docking sites in the syndecan extracellular domains may serve to localize other receptors to these sites as well, including integrins and growth factor receptor tyrosine kinases. A prototype of this mechanism is capture of the αvβ3 integrin and insulin-like growth factor 1 receptor (IGF1R) by syndecan-1 (Sdc1), forming a ternary receptor complex in which signaling downstream of IGF1R activates the integrin. This Sdc1-coupled ternary receptor complex is especially prevalent on tumor cells and activated endothelial cells undergoing angiogenesis, reflecting the up-regulated expression of αvβ3 integrin in such cells. As such, much effort has focused on developing therapeutic agents that target this integrin in various cancers. Along these lines, the site in the Sdc1 ectodomain that is responsible for capture and activation of the αvβ3 or αvβ5 integrins by IGF1R can be mimicked by a short peptide called 'synstatin', which competitively displaces the integrin and IGF1R kinase from the syndecan and inactivates the complex. This review summarizes our current knowledge of the Sdc1-coupled ternary receptor complex and the efficacy of synstatin as an emerging therapeutic agent to target this signaling mechanism.
authors: Department of Human Oncology, Carbone Comprehensive Cancer Center, Wisconsin Institutes for Medical Research, University of Wisconsin-Madison, Madison, WI 53705, USA. rapraeger@humonc.wisc.edu
authors: Alan C
authors: AC
authors: Rapraeger
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism; D002448:Cell Adhesion; D002471:Cell Transformation, Neoplastic; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D010455:Peptides / Q000494:pharmacology; D011485:Protein Binding; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D053668:Syndecan-1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D050801:Ternary Complex Factors / Q000378:metabolism*; D000099152:Cadherin 5
chemical_list: D015703:Antigens, CD; D015820:Cadherins; D039302:Integrin alphaVbeta3; D010455:Peptides; D017526:Receptor, IGF Type 1; D011994:Recombinant Proteins; D053668:Syndecan-1; D050801:Ternary Complex Factors; D000099152:Cadherin 5; C508241:SDC1 protein, human
references: J Cell Biol. 2005 Oct 24;171(2):383-92
references: 16247034
references: J Cell Biol. 2004 Oct 11;167(1):171-81
references: 15479743
references: Nat Rev Cancer. 2008 Aug;8(8):604-17
references: 18497750
references: J Biol Chem. 1997 May 16;272(20):12901-4
references: 9148893
references: Science. 2003 Oct 3;302(5642):103-6
references: 14526080
references: J Biol Chem. 2000 Jul 14;275(28):21340-8
references: 10766752
references: J Invest Dermatol. 1994 Sep;103(3):295-9
references: 8077694
references: J Clin Oncol. 1989 Dec;7(12):1909-14
references: 2585025
references: J Cell Biol. 2001 Oct 29;155(3):459-70
references: 11684710
references: J Cell Sci. 2008 Jul 1;121(Pt 13):2115-22
references: 18565824
references: Br J Cancer. 2002 Mar 4;86(5):788-95
references: 11875744
references: Physiol Rev. 2004 Jul;84(3):869-901
references: 15269339
references: Oncogene. 2007 Sep 13;26(42):6238-43
references: 17369840
references: Annu Rev Biophys. 2009;38:235-54
references: 19416068
references: Int J Cancer. 1997 May 2;71(3):320-4
references: 9139861
references: Am J Pathol. 1996 May;148(5):1423-34
references: 8623914
references: Exp Hematol. 2001 Aug;29(8):993-1003
references: 11495705
references: J Cell Sci. 2004 Feb 15;117(Pt 5):657-66
references: 14754902
references: Cell. 1994 Dec 30;79(7):1157-64
references: 7528107
references: Front Biosci. 1999 Feb 15;4:D188-99
references: 9989953
references: Exp Cell Res. 2007 Nov 1;313(18):3902-13
references: 17870067
references: EMBO J. 1999 Feb 15;18(4):882-92
references: 10022831
references: FEBS J. 2010 Oct;277(19):3904-23
references: 20840587
references: J Cell Sci. 2008 May 1;121(Pt 9):1345-7
references: 18434644
references: Blood. 2010 Mar 25;115(12):2449-57
references: 20097882
references: Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
references: 12516034
references: J Biol Chem. 2006 Oct 27;281(43):32156-63
references: 16936286
references: Curr Opin Cell Biol. 2011 Oct;23(5):630-7
references: 21565482
references: Angiogenesis. 2009;12(2):177-85
references: 19267251
references: Circ Res. 2007 Sep 14;101(6):536-8
references: 17872470
references: Mol Endocrinol. 2005 Jan;19(1):1-11
references: 15528274
references: Am J Pathol. 1998 Nov;153(5):1347-51
references: 9811323
references: Haematologica. 2002 Aug;87(8):836-45
references: 12161360
references: Diagn Mol Pathol. 1996 Jun;5(2):127-35
references: 8727100
references: J Cell Sci. 2006 Jun 15;119(Pt 12):2445-56
references: 16720645
references: J Clin Invest. 2000 Feb;105(4):433-40
references: 10683372
references: J Biol Chem. 2000 Dec 22;275(51):39867-73
references: 10964931
references: FASEB J. 2002 Aug;16(10):1266-8
references: 12153995
references: J Cell Sci. 2010 Nov 1;123(Pt 21):3796-807
references: 20971705
references: Blood. 2003 Feb 1;101(3):1128-40
references: 12393520
references: Neoplasia. 2008 Nov;10(11):1259-67
references: 18953435
references: Genes Dev. 1999 Feb 1;13(3):295-306
references: 9990854
references: Science. 2000 Sep 1;289(5484):1504-8
references: 10968780
references: J Biol Chem. 1998 Oct 23;273(43):28270-6
references: 9774449
references: FEBS J. 2013 May;280(10):2194-206
references: 23331867
references: J Exp Med. 2009 Mar 16;206(3):691-705
references: 19255147
references: J Biol Chem. 2005 Feb 4;280(5):3151-8
references: 15546884
references: Int Rev Cytol. 2001;207:113-50
references: 11352265
references: Clin Cancer Res. 2000 Aug;6(8):3056-61
references: 10955784
references: Cancer Res. 2001 Mar 1;61(5):2232-8
references: 11280792
references: Science. 1994 Apr 22;264(5158):569-71
references: 7512751
references: J Biol Chem. 2009 Feb 20;284(8):5119-27
references: 19098287
references: Circ Res. 2007 Sep 14;101(6):570-80
references: 17641225
references: J Biol Chem. 2008 Oct 24;283(43):29322-30
references: 18753130
references: J Cell Sci. 2009 Jan 15;122(Pt 2):159-63
references: 19118207
references: Exp Cell Res. 2003 Jun 10;286(2):219-32
references: 12749851
references: Anticancer Agents Med Chem. 2006 Sep;6(5):407-28
references: 17017851
references: IDrugs. 2001 Jan;4(1):72-81
references: 16034705
references: Mol Biol Cell. 1997 Dec;8(12):2449-61
references: 9398667
references: Nature. 2000 Sep 14;407(6801):249-57
references: 11001068
references: Oncogene. 2003 Dec 8;22(56):9022-9
references: 14663480
references: J Biol Chem. 2002 Mar 15;277(11):8955-60
references: 11779860
references: Science. 1995 Dec 1;270(5241):1500-2
references: 7491498
references: FEBS J. 2010 Oct;277(19):3876-89
references: 20840585
references: J Cell Biol. 1998 Dec 28;143(7):2081-92
references: 9864377